<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020332</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068292</org_study_id>
    <secondary_id>NCI-00-C-0212</secondary_id>
    <secondary_id>NCI-952</secondary_id>
    <nct_id>NCT00020332</nct_id>
    <nct_alias>NCT00006277</nct_alias>
  </id_info>
  <brief_title>Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of docetaxel and flavopiridol in patients with&#xD;
           previously treated locally advanced or metastatic breast cancer.&#xD;
&#xD;
        -  Determine the dose-limiting toxicity, toxicity profile, and pharmacokinetics of this&#xD;
           regimen in these patients.&#xD;
&#xD;
        -  Determine the activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the objective response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine immune dysfunction produced by this regimen as measured by lymphocyte&#xD;
           subpopulations, including T-cell activation/memory subsets and natural killer&#xD;
           cell/lymphokine-activated killer cell functional subsets in these patients.&#xD;
&#xD;
        -  Determine the ability of positron emission tomography scanning to predict response in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the response duration, time to treatment failure, and overall survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine whether this regimen is associated with the development of a prothrombotic&#xD;
           state in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on day 1 followed by flavopiridol IV over 1 hour or&#xD;
      IV continuously on days 2-4. Treatment repeats every 3 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Sequential dose escalation of docetaxel is preceded or followed by sequential dose escalation&#xD;
      of flavopiridol. Cohorts of 3-6 patients receive escalating doses of docetaxel preceded or&#xD;
      followed by escalating doses of flavopiridol until the maximum tolerated dose (MTD) of the&#xD;
      combination is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, 22 additional&#xD;
      patients are accrued to receive flavopiridol and docetaxel at the recommended phase II dose.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 3 courses during study, and then at completion&#xD;
      of study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 49 patients (27 for phase I and 22 for phase II) will be&#xD;
      accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage III or IV adenocarcinoma of the breast&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  Evaluable disease allowed&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  At least 1 site of measurable disease&#xD;
&#xD;
          -  No bone metastasis as only site of disease&#xD;
&#xD;
          -  No carcinomatous meningitis or brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No active coagulopathy requiring therapeutic anticoagulation&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  No Gilbert's disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 50% without clinical signs or symptoms of&#xD;
             heart failure&#xD;
&#xD;
          -  No uncontrolled hypertension (sustained systolic blood pressure (BP) greater than 180&#xD;
             mm Hg or diastolic BP greater than 100 mm Hg)&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No significant ischemia or valvular heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No medical or psychiatric condition that would increase risk&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             nonmelanomatous skin cancer&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No diabetes mellitus with a fasting blood sugar greater than 200 mg/dL&#xD;
&#xD;
          -  No active unresolved infection&#xD;
&#xD;
          -  No serious concurrent medical illness&#xD;
&#xD;
          -  No history of hypersensitivity reaction to products containing polysorbate 80 (Tween&#xD;
             80)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior flavopiridol&#xD;
&#xD;
          -  Prior adjuvant chemotherapy for advanced disease allowed if within 6 months of&#xD;
             diagnosis of metastatic disease&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or 8 weeks for&#xD;
             UCN-01) and recovered&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  Any number of prior chemotherapy regimens for metastatic carcinoma of the breast&#xD;
                  allowed&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No more than 2 prior chemotherapy regimens for metastatic carcinoma of the breast&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapy in the metastatic or adjuvant setting allowed&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy and no evidence of disease improvement&#xD;
             by radiography after therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed if for study premedication or hypersensitivity&#xD;
             reactions/adverse events&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent antineoplastic therapies&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinette R. Tan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2002</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

